Roswell Park Introduces Gyn-Onc Connect Line for Consultation - Report - MDSpire

Roswell Park Introduces Gyn-Onc Connect Line for Consultation

  • By

  • June 29, 2026

  • 1 min

Share

Clinical Report: Roswell Park Introduces Gyn-Onc Connect Line for Consultation

Overview

Roswell Park Comprehensive Cancer Center has launched Gyn-Onc Connect, a dedicated phone line for healthcare providers to access gynecologic oncology expertise. This initiative provides information on clinical trials and treatment options.

Background

Access to specialized oncology care is crucial for managing complex gynecologic cancer cases. The introduction of Gyn-Onc Connect improves communication between community practitioners and specialized oncology teams, facilitating timely consultations and guidance for treatment decisions.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

  • Gyn-Onc Connect provides a direct line for physicians to consult with Roswell Park’s gynecologic oncology team.
  • The service is designed to assist with case discussions and treatment guidance.
  • It offers access to information about open clinical trials at Roswell Park.
  • Roswell Park emphasizes multidisciplinary care from recognized specialists in gynecologic oncology.
  • Innovative clinical trials are available that are not offered elsewhere in the region.

Clinical Implications

Healthcare providers can utilize Gyn-Onc Connect to access specialized knowledge and resources for managing gynecologic cancer patients.

Conclusion

The launch of Gyn-Onc Connect supports community practitioners in the management of gynecologic oncology cases.

Related Resources & Content

  1. Roswell Park Comprehensive Cancer Center, New Immunotherapy Trials Offer Hope to Previously Excluded Gynecologic Cancer Patients, 2025 -- New Immunotherapy Trials Offer Hope to Previously Excluded Gynecologic Cancer Patients
  2. Roswell Park Comprehensive Cancer Center, Join Roswell Park Experts at ASCO, 2025 -- Join Roswell Park Experts at ASCO
  3. Roswell Park Comprehensive Cancer Center, Register for Roswell Park’s Fall Oncology Symposium, 2025 -- Register for Roswell Park’s Fall Oncology Symposium
  4. roswell park comprehensive cancer center — Meet the Team: Nicole Gaulin, MD
  5. Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. | Journal of Clinical Oncology
  6. KEYNOTE-A18 - Clinical Findings and Study Design
  7. Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing? - Penninx - 2025 - Cancer - Wiley Online Library
  8. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025 - PubMed
  9. THE LANCET OncologySupplementary appendixThis appe
  10. SEOM-GEICO clinical guidelines on endometrial cancer (2025) - PMC
  11. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer - PMC
  12. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update | Journal of Clinical Oncology
  13. Final MIRASOL Trial Analysis Confirms Consistent Efficacy of Mirvetuximab Soravtansine | AJMC
  14. The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis - PMC

Original Source(s)

Related Content